Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
ORIC Pharmaceuticals revenue
ORIC Pharmaceuticals's revenue is $450.9 million.
What is ORIC Pharmaceuticals's revenue?
- ORIC Pharmaceuticals has 61 employees, and the revenue per employee ratio is $7,391,689.
- ORIC Pharmaceuticals peak revenue was $450.9M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
ORIC Pharmaceuticals financing
ORIC Pharmaceuticals received early financing of $15.0M on 2014-11-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $15M | 11/2014 |
| Series B | $53M | 12/2015 |
| Series C | $50M | 02/2018 |
| Series D | $55M | 08/2019 |
ORIC Pharmaceuticals investors
| Investors | Security type |
|---|---|
| The Column Group | Series A |
| Topspin Partners | Series B |
| EcoR1 Capital, LLC | Series B |
| OrbiMed | Series B |
| Foresite Capital | Series B |
| KKR & Co. Inc. | Series B |
| The Column Group | Series B |
| EcoR1 Capital, LLC | Series C |
| Memorial Sloan - Kettering Cancer Center | Series C |
| Kravis Investment Partners | Series C |
| Taiho Ventures LLC | Series C |
| NS Investment | Series C |
| Trinitas Capital | Series C |
| Foresite Capital | Series C |
| OrbiMed | Series C |
| Topspin Fund | Series C |
| Fidelity Management & Research Co LLC | Series C |
| The Column Group | Series C |
| Topspin Partners | Series D |
| EcoR1 Capital, LLC | Series D |
| Hartford HealthCare Endowment | Series D |
| City Hill Ventures | Series D |
| Memorial Sloan - Kettering Cancer Center | Series D |
| Correlation Ventures | Series D |
| Kravis Investment Partners | Series D |
| ArrowMark Partners | Series D |
| The Column Group | Series D |
| Fidelity Management & Research Co LLC | Series D |
| Invus | Series D |
| Taiho Ventures LLC | Series D |
| Foresite Capital | Series D |
| OrbiMed | Series D |
| Casdin Capital | Series D |
| Irving Investors | Series D |
ORIC Pharmaceuticals competitors
ORIC Pharmaceuticals's top competitor, PTC Therapeutics, earned an annual revenue of $806.8M.
ORIC Pharmaceuticals's smallest competitor is Onconova Therapeutics with revenue of $226.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| PTC Therapeutics | - | $806.8M | 517 | - |
| Constellation Pharmaceuticals | - | $4.7M | 82 | - |
| Novan | - | $23.7M | 63 | - |
| Prelude Therapeutics | - | $7.0M | 70 | - |
| eFFECTOR Therapeutics | - | $42.0M | 24 | - |
| Deciphera Pharmaceuticals | - | $163.4M | 200 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Spring Bank Pharmaceuticals | - | $64.9M | 84 | - |
| Fate Therapeutics | - | $13.6M | 104 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
ORIC Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of ORIC Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ORIC Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at ORIC Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ORIC Pharmaceuticals. The data presented on this page does not represent the view of ORIC Pharmaceuticals and its employees or that of Zippia.
ORIC Pharmaceuticals may also be known as or be related to ORIC PHARMACEUTICALS, INC., ORIC Pharmaceuticals, ORIC Pharmaceuticals Inc, ORIC Pharmaceuticals, Inc. and Oric Pharmaceuticals, Inc.